Supplementary Figure S2 from A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer – The MONEO Study

Key Points

Main finding reveals a significant association between tertiary lymphoid structures and tumor response in gastric cancer patients.
Key evidence shows that the presence of these structures may predict better responses to avelumab combined with chemotherapy.
Approach involved analyzing surgical tumor samples to distinguish responses based on the presence of tertiary lymphoid structures.
Significance lies in identifying potential biomarkers that could improve treatment strategies for patients with gastric malignancies.

Phase II trial discovers tumor response links to tertiary lymphoid structures in gastric cancer patients, indicating a potential new biomarker.

Supplementary Figure 2: Tertiary lymphoid structures in surgical tumor samples, analysed separately depending on tumor response.

No takes yet. Share an insight, caveat, or question.

Alsina et al. (2025) studied this question.

View at Publisher

Ask AI

Bookmark

Share